重组甘精胰岛素联合瑞格列奈治疗老年2型糖尿病疗效分析

目的:评价重组甘精胰岛素(长秀霖)联合瑞格列奈治疗老年2型糖尿病的临床疗效。方法:将110例口服降糖药控制不理想的老年2型糖尿病患者随机分为对照组与观察组,给予58例观察组患者重组甘精胰岛素(长秀霖)注射,给予52例对照组患者中效胰岛素诺和灵N注射,两组同时均口服瑞格列奈治疗。比较两组治疗4个月后血糖控制情况、达标时间及低血糖发生率。结果:观察组患者空腹血糖、餐后血糖及糖化血红蛋白显著优于对照组,比较差异具有统计学意义(P<0.05);观察组与对照组血糖达标时间分别为(6.59±1.12)周、(8.92±1.07)周(P<0.05);两组低血糖发生率分别为36.2%和76.9%,观察组显著少于对照组(P<0.01)。结论:相对于中效胰岛素诺和灵N,重组甘精胰岛素联合瑞格列奈治疗老年2型糖尿病血糖控制良好,低血糖发生率低,作为老年人胰岛素基础治疗,更具有选择优势。

Clinical efficiency of recombinant insulin glargine combining with repaglinide in elder patients with type 2 diabetes mellitus

Objective: To evaluate the clinical recombinant insulin glargine combining with repaglinide in elder patients with type 2 diabetes mellitus.Methods:A total of 110 elder patients with type 2 diabetes mellitus whose glucose levels were inadequately controlled were randomly divided into control and observation group.The observation group(58 cases) was given Changxiuling injection daily,while 52 patients in the control group were given NPH.Both groups were given oral administration of repaglinide.After 4 months of treatment,glycemia,time requirds and incidence of hypoglycemia in two groups were analyzed and compared.Results:Fasting glucose,2h postprandial glucose,glycosylated hemoglobin of the observation group were significant better than that of the control group(P<0.05);it took(6.59±1.12) and(8.92±1.07) weeks for the observation group and control group to restore normal glucose levels(P<0.05);The incidence of hypoglycemia was significantly lower in experience group than that in control group(36.2% vs 76.9%,P<0.01).Conclusions:Comparing with NPH,recombinant insulin glargine combining with repaglinide shows better effects for glucose control and lower incidence of hypoglycemia in elder patients with type 2 diabetes mellitus,and is a superior choice for those patients.